Search Results - Rasmus Offersen

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 <sup>+</sup> T Cells

    A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 <sup>+</sup> T Cells by Rasmus Offersen, Sara Konstantin Nissen, Thomas A. Rasmussen, Lars Østergaard, Paul W. Denton, Ole S. Søgaard, Martin Tolstrup

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Identification of Novel Genetic Variants in CVID Patients With Autoimmunity, Autoinflammation, or Malignancy

    Identification of Novel Genetic Variants in CVID Patients With Autoimmunity, Autoinflammation, or Malignancy by Mette Christiansen, Rasmus Offersen, Jens Magnus Bernth Jensen, Mikkel Steen Petersen, Carsten Schade Larsen, Trine H. Mogensen

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

    Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection by Line K. Vibholm, Mariane Høgsbjerg Schleimann, Jesper Falkesgaard Højen, Thomas Benfield, Rasmus Offersen, Katrine Laura Rasmussen, Rikke Olesen, Anders Dige, Jørgen Agnholt, Judith Grau-Expósito, María J. Buzón, Burghardt Wittig, Mathias Lichterfeld, Andreas Munk Petersen, Xutao Deng, Mohamed Abdel‐Mohsen, Satish K. Pillai, Sofie Rutsaert, Wim Trypsteen, Ward De Spiegelaere, Linos Vandekerchove, Lars Østergaard, Thomas A. Rasmussen, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

    Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. by Jesper Damsgaard Gunst, Nina Breinholt Stærke, Marie H. Pahus, Lena Hagelskjær Kristensen, Jacob Bodilsen, Nicolai Lohse, Lars Dalgaard, Dorthe Brønnum, Ole Fröbert, Bo Langhoff Hønge, Işık Somuncu Johansen, Ida Monrad, Christian Erikstrup, Regitze Rosendal, Emil Vilstrup, Theis Mariager, Dorthe Gaby Bové, Rasmus Offersen, Shakil Shakar, Sara Cajander, Nis Pedersen Jørgensen, Sajitha Sophia Sritharan, Peter Breining, S.K. Jespersen, Klaus Leth Mortensen, Mads Langballe Jensen, Lilian Kolte, Giacomo S. Frattari, Carsten Schade Larsen, Merete Storgaard, Lars Peter Nielsen, Martin Tolstrup, Eva Aggerholm Sædder, Lars Østergaard, Hien T. T. Ngo, Morten Hasselstrøm Jensen, Jesper Falkesgaard Højen, Mads Kjølby, Ole S. Søgaard

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: